Metallothionein expression in hepatocellular carcinoma

Geng-Wen Huang, Lian-Yue Yang

AIM: To investigate the expression of metallothioneins (MTs), which were recently thought to have close relationship with tumors, in human hepatocellular carcinoma.

METHODS: Histological specimens of 35 cases of primary human hepatocellular carcinoma with para-neoplastic liver tissue and 5 cases of normal liver tissue were stained for MTs with monoclonal mouse anti-MTs serum (E9) by the immunohistochemical ABC technique.

RESULTS: MTs were stained in the 35 cases of HCC, including 6 cases negative (17.1 %), 23 weakly positive (65.7 %), and 6 strongly positive (17.1 %). But MTs were stained strongly positive in all the five cases of normal liver and 35 cases of para-neoplastic liver tissue. The differences of MTs expression between HCC and normal liver tissue or para-neoplastic liver tissue were highly significant (P<0.01). The rate of MTs expression in HCC grade I was 100 percent, higher than that in grade II (81 %) and grade III and IV (78 %). But the differences were not significant (P>0.05). No obvious correlations between MTs expression in HCC and tumor size, clinical stage or serum alpha fetoprotein concentration were found (P>0.05).

CONCLUSION: Decrease of MTs expression in HCC may play a role in carcinogenesis of HCC. MTs are stained heterogeneously in HCC. We can choose the anticancer agents according to the MTs concentration in HCC, which may improve the results of chemotherapy for HCC.


INTRODUCTION

Metallothioneins (MTs) are a family of low-molecular weight, cysteine rich proteins which are widely distributed in various species. MTs are thought to be involved in heavy-metal detoxification, intracellular trace elements storage and scavenging free radicals. Recently, emerging data suggest that MTs have close relationship with tumors. They might play important roles in carcinogenic and apoptotic process and differentiation of tumor cells[1-12]. And besides, MTs are attributed to affording tumor cells resistance to some important chemotherapeutic agents[13]. This study is aimed to examine MTs expression in human hepatocellular carcinoma (HCC) and to explore its biological and clinical significance.

MATERIALS AND METHODS

Clinical material

The clinical information and pathological specimens from 35 patients, whose liver tumors were removed at XiangYa Hospital from 1998 to 2000, were analyzed. All the cases were reviewed to confirm the pathological diagnosis of HCC. All the 35 specimens of HCC contained their corresponding para-neoplastic liver tissue. The ages of patients ranged from 31 to 71 years, with a mean ± SD of 49.92 ± 9.32 years. 33 were men and 2 women. According to Edmonson pathologic grading, there were 5 cases of grade I, 16 grade II and 14 grade III-IV. According to the clinical staging of UICC, there were 22 cases of stage II, 5 stage III and 8 stage IV. All the cases had positive HBsAg. This study also included 5 cases of normal liver tissue, around the hepatic hemangioma excised also in XiangYa Hospital.

Immunohistochemical determination of MTs

All the specimens were fixed in 10 % buffered formalin and embedded in paraffin. Five-micrometre thick sections were cut from the tissue blocks, mounted onto glass slides and were used for staining. ABC technique was adopted. Briefly, 5 μm sections were deparaffinized and rehydrated first, and then were immersed in 3 % H2O2 with methanol for 30 minutes to remove the endogenous peroxidase activity. Sections were further incubated with 10 % normal goat serum for 1 hour, followed by incubation with monoclonal mouse anti-MTs serum (E9) (1:50) at 4 °C overnight. The sections were then washed in phosphate buffer solution (PBS) (0.01M, pH 7.2) and they were sequentially incubated with: (1) biotinylated goat anti-mouse IgG, and (2) avidin-biotin horseradish peroxidase complex following the manufacturers’ instruction (ABC kit, BOSTER Ltd. Wuhan). Staining was developed by immersing slides in 0.05 % 3,3'-diaminobenzidine tetrahydrochloride (DAB) with 0.33 % hydrogen peroxide. All slides were counterstained with haematoxylin, dehydrated and mounted. PBS substituted for the primary antibody was used as the negative control. According to the proportion of positively stained cells, a grade was given from I to III, with Grade I indicating less than one third of cells stained and Grade III indicating more than two thirds of cells stained. The intensity of MTs expression was also graded and given a grade for 0 to II, with Grade 0 indicating no staining, and Grade II indicating the greatest intensity of staining. A weighted score was then generated to semiquantify the MTs expression level in the tissue by multiplying the MTs intensity score with the proportion of the positively stained tumors cells. A weighted score of zero indicated no MTs staining (-), more than 3 indicated strongly positive MTs staining (+++) and that between zero and 3 indicated weakly positive MTs staining (+)[14].

Statistical analysis

The data were expressed semiquantitatively. Ridit test was used to determine the difference. The results were considered statistically significant when P<0.05.
RESULTS

All negative control slides showed no staining for MTs, demonstrating the specificity of the monoclonal antibody E9. Strongly positive MTs immunoreactivity was observed in all the five control normal liver sections, mostly in cytoplasm with a few in nucleus. All the surrounding connective tissues, including blood vessels and bile ducts were negative for MTs staining. Twenty-nine of 35 HCC showed positive MTs staining, including 6 strongly positive (17.1 %) (Figure 1), 23 weakly positive (65.7 %) (Figure 2) and 6 negative (17.1 %) (Figure 3). MTs expressed strongly in all the para-neoplastic liver tissue. The differences of MTs expression between HCC and para-neoplastic liver tissue or normal liver tissue were highly significant (Table 1, \( P < 0.01 \)).

The positive ratio of MTs expression in grade I of HCC was 100 %, higher than that in grade II (81 %) and grade III and IV (78 %). But the differences did not reached the level of significance \( (P>0.05) \). In addition, the differences of MTs expression in HCC with different clinical stages, tumor sizes and serum alpha fetoprotein concentration were not significant either (Table 2).

Table 1 Levels of MTs expression in HCC, para-neoplastic and normal liver tissues

<table>
<thead>
<tr>
<th>MTs score</th>
<th>n</th>
<th>-</th>
<th>+</th>
<th>++</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCC</td>
<td>35</td>
<td>6</td>
<td>23</td>
<td>6</td>
</tr>
<tr>
<td>Para-neoplastic tissue</td>
<td>35</td>
<td>0</td>
<td>0</td>
<td>35</td>
</tr>
<tr>
<td>Normal liver tissue</td>
<td>5</td>
<td>0</td>
<td>0</td>
<td>5</td>
</tr>
</tbody>
</table>

\( ^* P < 0.01, \text{ vs HCC} \)

Table 2 Correlation between MTs expression and clinicopathologic data of HCC

<table>
<thead>
<tr>
<th>MTs score</th>
<th>n</th>
<th>-</th>
<th>+</th>
<th>++</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pathologic grade</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade I</td>
<td>5</td>
<td>0</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Grade II</td>
<td>16</td>
<td>3</td>
<td>10</td>
<td>3</td>
</tr>
<tr>
<td>Grade III-IV</td>
<td>14</td>
<td>3</td>
<td>10</td>
<td>1</td>
</tr>
<tr>
<td>Clinical stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage I-II</td>
<td>22</td>
<td>5</td>
<td>14</td>
<td>3</td>
</tr>
<tr>
<td>Stage III-IV</td>
<td>13</td>
<td>1</td>
<td>9</td>
<td>3</td>
</tr>
<tr>
<td>Size (mm)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>( \leq 50 )</td>
<td>9</td>
<td>3</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>( &gt;50 )</td>
<td>26</td>
<td>3</td>
<td>17</td>
<td>6</td>
</tr>
<tr>
<td>AFP concentration (ng/ ml)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>( \leq 50 )</td>
<td>13</td>
<td>3</td>
<td>6</td>
<td>4</td>
</tr>
<tr>
<td>( &gt;50 )</td>
<td>22</td>
<td>3</td>
<td>17</td>
<td>2</td>
</tr>
</tbody>
</table>

DISCUSSION

Recently, much attention was paid to the association between MTs and tumors. Available information suggested that MTs might play important roles in carcinogenic and apoptotic process of some tumors. Using immunohistochemical staining method, MTs have been localized intensively in various types of human tumors in organs and tissues such as skin, kidneys, prostate, testes, gallbladder, colon, breast and endometrium. It was mainly attributed to loss of control of the transcription of MTs genes, which was caused by activation of some oncogenes, such as Ha-ras, in tumor cells. However, the potential roles of MTs in carcinogenic process was not yet well understood. Several pieces of evidence suggested that MTs could combine with and sequester those carcinogenic substances in cells. When the cells were invaded by the carcinogenic substances, many protective processes were activated to scavenge those substances. Elevation of MTs may be one of the processes. But not all the tumors contained...
elevated MTs expression, such as HCC. In this study, the authors have detected MTs expression in 35 cases of HCC and their corresponding para-neoplastic liver tissue and 5 cases of normal liver tissue. The results showed that MTs were strongly positive in all the normal liver tissue and para-neoplastic liver tissue, considerably higher than those in HCC tissue, which conformed to the finding of Deng et al. MTs are functional proteins in liver tissue, which is involved in heavy metal detoxification. The down-regulation of MTs expression in HCC suggested that these cells probably have different proliferative or differentiated characteristics as compared to the surrounding normal hepatocytes, and MTs may be a marker of hepatocellular differentiation. In addition, this down-regulation might play a role in carcinogenic process of HCC. MTs are one of the most important intracellular free radicals scavengers, and oxidative injury may be one of the most important causes of gene mutation. As a result, this down-regulation of MTs expression might cause accretion of oxidative in cells, which might lead to activating some oncogenes or inactivating some tumor-suppressor genes.

Several other studies have also shown that the MTs levels may be related to the degree of differentiation of tumor cells. For example, using immunohistochemical staining method, a distinct difference between seminoma and nonseminoma of human testicular tumors was found. Well-differentiated seminoma showed litter or no staining for MTs while less differentiated nonseminoma (embryonic carcinoma) strongly expressed MTs. MTs overexpression in human breast carcinoma, colorectal carcinoma, esophageal carcinoma, osteosarcoma, endometrial carcinoma and melanoma tended to correlate with poor prognosis. In this study, the positive rate of MTs expression in grade I of HCC is 100 percent, higher than grade II (81 %) and grade III and IV (78%), but the differences have not reach the level of significance. So the genuine relationship between MTs and differentiation of HCC remains to be further investigated.

Resistance to antineoplastic agents is one of the major obstacles to curative therapy of HCC. The development of this resistance has been explained by several factors, including increased DNA repair processes and expression of MDR gene. In 1998, Kelley et al. found that tumor cell lines with acquired resistance to the antineoplastic agent cisplatin overexpressed MTs and demonstrated cross-resistance to other electrophilic anticancer agents, such as melphanal, chlorambucil. Furthermore, cells transfected with bovine papilloma virus expression vectors containing DNA encoding human MTs were resistant to electrophilic anticancer drugs mentioned above, but not to 5-fluorouracil or vincristine. Thus, overexpression of MTs represented one mechanism of resistance to a subset of clinically important anticancer drugs. Those results were substantiated by a series of other experiments. The mechanism that MTs were involved in drug resistance might be that MTs in tumor cells could combine with those electrophilic anticancer drugs and prevent them from acting on their targets, such as DNA. In this study, we have shown that MTs expressed heterogeneously in HCC, including 6 cases with strong expression, 23 with weak expression and 6 negative. The authors therefore assumed that resistance to electrophilic antineoplastic agents in a portion of HCC might be related to MTs expression in tumor tissue.

Thus, anticancer agents could be chosen according to the levels of MTs expression in order to improve the efficiency of chemotherapy for HCC. For example, electrophilic antineoplastic agents were used in the treatment of HCC without MTs and non-electrophilic antineoplastic agents were used in HCC containing high levels of MTs. However, the effect of this design remains to be determined. Recently, a gene therapy by transactivating MTs to the chemoresistant tumour cells to reverse the chemoresistance have been reported. In the near future, oncologists are really able to use the knowledge about MTs in overcoming cancer.

The down-regulation of MTs expression in HCC might play roles in carcinogenesis of HCC, but its biological and clinical significance is still uncertain. A further understanding of the association between MTs expression and resistance to anticancer agents should facilitate the chemotherapy for HCC.

REFERENCES


www.wjgnet.com
Metallothionein expression in hepatocellular carcinoma

2001; 165: 1710-1713

Application of metallothionein in new bioassays. Hum Pathol 1999; 30: 75-81

Schmidt CJ. Marker specificity of on human metallothionein gene expression. Proc Natl Acad Sci USA 1986; 83:3346-3350


39 Rossman TG, Goncharova EL. Spontaneous mutagenesis in mammalian cells is caused mainly by oxidative events and can be blocked by antioxidants and metallothionein. Mutat Res 1998; 402:103-110


41 Duncan EL, Redd DR. Downregulation of metallothionein-IIA expression occurs at immortalization. Oncogene 1999; 18: 897-903

42 Floriszczyk B, Grzybowska L. Metallothionein in levels in cell fractions from breast cancer tissues. Acta Oncol 2000; 39: 141-143


Edited by Zhang JZ

www.wjgnet.com